Trial
NCT05360264
tailOred dRug repurposIng of dEcitabine in KRAS-dependeNt refracTory pAncreaTic cancEr
Phase IITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
Luca Cardone
Collaborators
Anticancer Fund, Belgium; Azienda Ospedaliera Universitaria Integrata Verona; Catholic University of the Sacred Heart; Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale; San Raffaele University Hospital, Italy; University of Pisa
Condition
Pancreatic Adenocarcinoma Metastatic
Intervention
Decitabine 50 MG [Dacogen]
Why stopped
Unexpected toxicity events were documented during interim safety evaluations of the investigational drug.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-03-24